Investor Presentaiton
Investor presentation
Full year 2018
Sales growth of 5% mainly driven by Victoza®, OzempicⓇ
and SaxendaⓇ
changing
diabetes
Sales as reported – full year 2018
Growth
Other
disorders biopharmaceuticals
3%
(11%)
Haemophilia
%
(9%)
6%
9%
Obesity
3%
51%
81%
Slide 5
Growth break down - full year 2018
Local currencies
Growth
Share of growth
Long-acting insulin¹
(2%)
(7%)
Premix insulin²
0%
0%
Fast-acting insulin³
1%
3%
Human insulin
(1%)
(3%)
Diabetes care
0%
Total insulin
(1%)
(7%)
GLP-14
18%
78%
Other diabetes care5
3%
2%
Total diabetes care
4%
73%
Obesity (SaxendaⓇ)
60%
30%
Diabetes care and obesity total
6%
103%
Haemophilia
(5%)
(10%)
Growth disorders (NorditropinⓇ)
7%
9%
Other biopharmaceuticals?
(8%)
(2%)
Biopharmaceuticals
(1%)
(3%)
5%
100%
Sales of DKK 111.8 billion (0%)
Total
1 Comprises Tresiba®, XultophyⓇ and LevemirⓇ; 2 Comprises RyzodegⓇ and NovoMix®
3 Comprises FiaspⓇ and NovoRapidⓇ; 4 Comprises VictozaⓇ and OzempicⓇ
5 Primarily Novo NormⓇ and needles; 6 Comprises NovoSeven®, NovoEight® NovoThirteenⓇ and Refixia®;
7 Primarily Vagifem® and ActivelleⓇ
Note: Refixia® and NovoThirteenⓇ are launched as RebinynⓇ and TRETTENⓇ, respectively, in the USAView entire presentation